John F. Paolini

CIK: 0001741533

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)20 (26.7%)

Position reduction

Option Exercises (M)28 (37.3%)

Derivative conversions

Awards (A)16 (21.3%)

Compensation grants

Other (G, F, J, C, D, …)11 (14.7%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

KNSA

Kiniksa Pharmaceuticals International, plc

Discretionary Trading P&L

Holdings

Transaction History (75 total)

KNSA
Kiniksa Pharmaceuticals International, plc
Nov 2, 2026
Sale(S)
Direct
899 shares at avg. $92.37$83K
KNSA
Kiniksa Pharmaceuticals International, plc
Nov 2, 2026
Exercise(M)
Direct
12K shares at avg. $17.92$214K
KNSA
Kiniksa Pharmaceuticals International, plc
Nov 2, 2026
Exercise(M)
Direct
6.5K shares at avg. $30.93$200K
KNSA
Kiniksa Pharmaceuticals International, plc
Nov 2, 2026
Sale(S)
Direct
16.8K shares at avg. $93.42$1.6M
KNSA
Kiniksa Pharmaceuticals International, plc
Nov 2, 2026
Sale(S)
Direct
704 shares at avg. $94.09$66K
KNSA
Kiniksa Pharmaceuticals International, plc
Oct 30, 2026
Sale(S)
Direct
4.8K shares at avg. $94.86$457K
KNSA
Kiniksa Pharmaceuticals International, plc
Oct 30, 2026
Sale(S)
Direct
6.8K shares at avg. $93.91$642K
KNSA
Kiniksa Pharmaceuticals International, plc
Oct 30, 2026
Sale(S)
Direct
41.8K shares at avg. $92.02$3.8M
KNSA
Kiniksa Pharmaceuticals International, plc
Oct 30, 2026
Exercise(M)
Direct
39K shares at avg. $17.92$700K
KNSA
Kiniksa Pharmaceuticals International, plc
Oct 30, 2026
Exercise(M)
Direct
38.5K shares at avg. $30.93$1.2M
KNSA
Kiniksa Pharmaceuticals International, plc
Oct 30, 2026
Sale(S)
Direct
2.2K shares at avg. $97.77$211K
KNSA
Kiniksa Pharmaceuticals International, plc
Oct 30, 2026
Sale(S)
Direct
1.9K shares at avg. $97.06$187K
KNSA
Kiniksa Pharmaceuticals International, plc
Oct 30, 2026
Sale(S)
Direct
16.1K shares at avg. $92.85$1.5M
KNSA
Kiniksa Pharmaceuticals International, plc
Oct 30, 2026
Sale(S)
Direct
4K shares at avg. $95.97$384K
KNSA
Kiniksa Pharmaceuticals International, plc
Sep 1, 2026
Exercise(M)
Direct
2.5K shares-
KNSA
Kiniksa Pharmaceuticals International, plc
Sep 1, 2026
Exercise(M)
Direct
1.8K shares-
KNSA
Kiniksa Pharmaceuticals International, plc
Sep 1, 2026
Tax Payment(F)
Direct
4K shares at avg. $79.28$319K
KNSA
Kiniksa Pharmaceuticals International, plc
Sep 1, 2026
Award(A)
Restricted Share Unit
Direct
6.7K shares-
KNSA
Kiniksa Pharmaceuticals International, plc
Sep 1, 2026
Exercise(M)
Direct
1.6K shares-
KNSA
Kiniksa Pharmaceuticals International, plc
Sep 1, 2026
Exercise(M)
Direct
2.5K shares-
KNSA
Kiniksa Pharmaceuticals International, plc
Sep 1, 2026
Award(A)
Share Option
Direct
26.8K shares-
KNSA
Kiniksa Pharmaceuticals International, plc
May 1, 2026
Sale(S)
Direct
37.3K shares at avg. $53.52$2.0M
KNSA
Kiniksa Pharmaceuticals International, plc
May 1, 2026
Sale(S)
Direct
21.1K shares at avg. $54.04$1.1M
KNSA
Kiniksa Pharmaceuticals International, plc
May 1, 2026
Exercise(M)
Direct
58.4K shares at avg. $10.36$605K
KNSA
Kiniksa Pharmaceuticals International, plc
Apr 7, 2026
Exercise(M)
Direct
2.5K shares-

		Type	Shares	Price		Ownership
Nov 2, 2026	KNSA Kiniksa Pharmaceuticals International, plc	Sale(S)	899	$92.37	$83,041	Direct
Nov 2, 2026	KNSA Kiniksa Pharmaceuticals International, plc	Exercise(M)	11,958	$17.92	$214,287	Direct
Nov 2, 2026	KNSA Kiniksa Pharmaceuticals International, plc	Exercise(M)	6,455	$30.93	$199,653	Direct
Nov 2, 2026	KNSA Kiniksa Pharmaceuticals International, plc	Sale(S)	16,810	$93.42	$1,570,390	Direct
Nov 2, 2026	KNSA Kiniksa Pharmaceuticals International, plc	Sale(S)	704	$94.09	$66,239	Direct
Oct 30, 2026	KNSA Kiniksa Pharmaceuticals International, plc	Sale(S)	4,821	$94.86	$457,320	Direct
Oct 30, 2026	KNSA Kiniksa Pharmaceuticals International, plc	Sale(S)	6,841	$93.91	$642,438	Direct
Oct 30, 2026	KNSA Kiniksa Pharmaceuticals International, plc	Sale(S)	41,789	$92.02	$3,845,424	Direct
Oct 30, 2026	KNSA Kiniksa Pharmaceuticals International, plc	Exercise(M)	39,042	$17.92	$699,633	Direct
Oct 30, 2026	KNSA Kiniksa Pharmaceuticals International, plc	Exercise(M)	38,545	$30.93	$1,192,197	Direct
Oct 30, 2026	KNSA Kiniksa Pharmaceuticals International, plc	Sale(S)	2,155	$97.77	$210,694	Direct
Oct 30, 2026	KNSA Kiniksa Pharmaceuticals International, plc	Sale(S)	1,925	$97.06	$186,841	Direct
Oct 30, 2026	KNSA Kiniksa Pharmaceuticals International, plc	Sale(S)	16,056	$92.85	$1,490,800	Direct
Oct 30, 2026	KNSA Kiniksa Pharmaceuticals International, plc	Sale(S)	4,000	$95.97	$383,880	Direct
Sep 1, 2026	KNSA Kiniksa Pharmaceuticals International, plc	Exercise(M)	2,457	-	$0	Direct
Sep 1, 2026	KNSA Kiniksa Pharmaceuticals International, plc	Exercise(M)	1,750	-	$0	Direct
Sep 1, 2026	KNSA Kiniksa Pharmaceuticals International, plc	Tax Payment(F)	4,029	$79.28	$319,419	Direct
Sep 1, 2026	KNSA Kiniksa Pharmaceuticals International, plc	Award(A) Restricted Share Unit	6,700	-	-	Direct
Sep 1, 2026	KNSA Kiniksa Pharmaceuticals International, plc	Exercise(M)	1,624	-	$0	Direct
Sep 1, 2026	KNSA Kiniksa Pharmaceuticals International, plc	Exercise(M)	2,497	-	$0	Direct
Sep 1, 2026	KNSA Kiniksa Pharmaceuticals International, plc	Award(A) Share Option	26,750	-	-	Direct
May 1, 2026	KNSA Kiniksa Pharmaceuticals International, plc	Sale(S)	37,327	$53.52	$1,997,741	Direct
May 1, 2026	KNSA Kiniksa Pharmaceuticals International, plc	Sale(S)	21,097	$54.04	$1,140,082	Direct
May 1, 2026	KNSA Kiniksa Pharmaceuticals International, plc	Exercise(M)	58,424	$10.36	$605,273	Direct
Apr 7, 2026	KNSA Kiniksa Pharmaceuticals International, plc	Exercise(M)	2,497	-	$0	Direct

1-25 of 75 transactions

About Paolini John F.

Paolini John F. (SEC CIK 0001741533) files insider reports with the SEC as CHIEF MEDICAL OFFICER of Kiniksa Pharmaceuticals International, plc (KNSA).

Signal8 holds 15 ownership filings by Paolini John F., all Form 4s, filed between Sep 4, 2024 and Nov 3, 2026. Those filings report 75 transactions, from Sep 1, 2024 to Nov 2, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Paolini John F.'s filings is in LONDON.

Recent filings by Paolini John F.

Nov 2, 2026: Open-market sale of KNSA shares (Form 4, code S).
Nov 2, 2026: Option exercises of KNSA shares (2 lines, Form 4, code M).
Nov 2, 2026: Open-market sales of KNSA shares (2 lines, Form 4, code S).
Oct 30, 2026: Open-market sales of KNSA shares (3 lines, Form 4, code S).
Oct 30, 2026: Option exercises of KNSA shares (2 lines, Form 4, code M).

Other insiders filing for Kiniksa Pharmaceuticals International, plc (KNSA)

Moat Ross, CHIEF OPERATING OFFICER
Megna Michael R, CHIEF ACCOUNTING OFFICER
Ragosa Mark, CHIEF FINANCIAL OFFICER
Patel Sanj K, CHAIRMAN & CEO
Quart Barry D, Director
Levy Richard S, Director

How to read Form 4 transaction codes